Biocon and Genentech reach global Pebrilzo biosimilar patent settlement establishing launch dates

Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.

The agreement resolves pending patent disputes and permits Biocon to launch Pebrilzo in the EU and UK from the first quarter of 2027, in the United States from the third quarter of 2028 and in other territories according to agreed timelines.

The settlement provides greater commercial planning certainty for the proposed oncology biosimilar, although actual launches remain subject to applicable regulatory approvals and market access requirements.

Field	Content
Article Type	Deals
Companies	Biocon; Genentech
Deal Type	Global patent settlement and licence agreement
Product	Pebrilzo
Molecule	Pertuzumab
Reference Product	Perjeta
Therapeutic Area	Oncology; HER2-targeted breast cancer treatment
Agreement Scope	Resolution of patent disputes and establishment of licensed biosimilar launch dates
EU and UK Launch Window	From Q1 2027
US Launch Window	From Q3 2028
Other Territories	During 2026–2028 or earlier in certain circumstances
Financial Terms	Not disclosed in supplied summary
Regulatory Status	Commercial launch remains subject to applicable marketing approvals
Geography	Global; including European Union, United Kingdom and United States
What Happened	Biocon and Genentech agreed to a global patent settlement permitting specified future launch windows for Pebrilzo.
Why It Matters	The agreement reduces patent-related uncertainty and establishes a clearer commercial pathway for a proposed pertuzumab biosimilar.
Strategic Rationale	Biocon secures licensed market-entry dates while Genentech resolves outstanding intellectual property disputes.
Key Takeaway	The settlement establishes commercial launch rights but does not itself constitute regulatory approval of Pebrilzo.
What to Watch	Regulatory decisions, launch execution, reimbursement arrangements and competitive dynamics in pertuzumab biosimilars.
Primary Source	Biocon announcement
Relevant Date	14 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com